# Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects

> **NCT01459419** · PHASE2 · UNKNOWN · sponsor: **Inspira Medical AB** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** anti-CD3 monoclonal antibody
- **DRUG:** Sodium Chloride placebo

## Key facts

- **NCT ID:** NCT01459419
- **Lead sponsor:** Inspira Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2013-05
- **Final completion:** 2013-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2011-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459419, "Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01459419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*